Catalyst Pharmaceuticals (CPRX) Other Operating Expenses (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Other Operating Expenses data on file, last reported at $24.2 million in Q1 2026.

• Quarterly Other Operating Expenses fell 11.29% year-over-year to $24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.7 million (up 9.01% YoY) and the FY2025 annual result came in at $124.8 million, up 17.44% from the prior year.
• Other Operating Expenses fell to $24.2 million in Q1 2026, from $35.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $35.5 million in Q4 2025 to a low of $5.9 million in Q1 2022.
• A 5-year average of $22.1 million and a median of $24.2 million in 2026 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2023 — Other Operating Expenses soared 179.75% — and 2026, when it fell 11.29%.
• Tracing CPRX's Other Operating Expenses over 5 years: stood at $11.8 million in 2022, then surged by 111.19% to $24.9 million in 2023, then advanced by 24.61% to $31.0 million in 2024, then increased by 14.69% to $35.5 million in 2025, then sank by 31.97% to $24.2 million in 2026.
• The last three Other Operating Expenses figures came in at $24.2 million (Q1 2026), $35.5 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.